Market Access/ News/ News Genentech’s Rituxan approved for rare skin disease Linda Banks autoimmune disease, FDA approval, Genentech, pemphigus vulgaris, PV, rare disease, Rituxan, Roche 0 Comment The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years. Share X Genentech’s Rituxan approved for rare skin disease https://pharmaphorum.com/news/genentechs-rituxan-rare-skin-disease/